Peter J. Laud

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

Antoní Torres, Nanshan Zhong, Jan Pachl et al. · The Lancet Infectious Diseases · 2017 · 427 citations

Antibiotics, Ceftazidime-avibactam Versus Meropenem, Respiratory Infection +5

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Yehuda Carmeli, J. Armstrong, Peter J. Laud et al. · The Lancet Infectious Diseases · 2016 · 399 citations

Urinary Tract Infections, Urology, Antimicrobial Susceptibility +11

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis

Daniëlle M. Gerlag, Jasper J. Haringman, Tom Smeets et al. · Arthritis & Rheumatism · 2004 · 154 citations

Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension

Robert A. Lewis, Christopher Johns, Marcella Cogliano et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 140 citations · Full text

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

Xinyu Qin, Binh Giang Tran, Min Ja Kim et al. · International Journal of Antimicrobial Agents · 2017 · 127 citations · Full text

Intra-abdominal Infections, Pharmacotherapy, Antimicrobial Chemotherapy +22